ReShape Lifesciences Inc. entered into an Equity Distribution Agreement with Maxim Group LLC to sell up to $9,700,000 of its common stock. On June 9, 2025, the company priced a public offering of 1,054,604 shares at $2.50 per share, expecting gross proceeds of $2,636,510. Since the start of the at-the-market offering, ReShape has sold $3,642,564 worth of shares, leaving $3,420,926 available under the agreement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.